• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Repare Therapeutics Inc.

    3/3/25 4:06:54 PM ET
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPTX alert in real time by email
    S-8 1 d889324ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 3, 2025

    Registration No. 333-  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Repare Therapeutics Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Québec   Not applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    7171 Frederick-Banting, Building 2,

    Suite 270

    St-Laurent, Québec, Canada

      H4S 1Z9
    (Address of Principal Executive Offices)   (Zip Code)

    Repare Therapeutics 2020 Equity Incentive Plan

    Repare Therapeutics 2020 Employee Share Purchase Plan

    (Full title of the plan)

    Lloyd M. Segal

    Chief Executive Officer

    Repare Therapeutics Inc.

    1 Broadway, 15th Floor

    Cambridge, MA 02142

    +1 857 412 7018

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Divakar Gupta

    Courtney Thorne

    Cooley LLP

    500 Boylston Street

    Boston, Massachusetts 02116

    +1 617 937 2300

     

    Robert Carelli

    Jeremy Sculnick

    Stikeman Elliott LLP

    1155 René-Lévesque Blvd. West

    41st Floor

    Montréal, Québec, Canada H3B 3V2

    +1 514 397 3222

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Repare Therapeutics Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (i) 2,125,535 additional common shares, no par value (the “Common Shares”), of the Registrant under the 2020 Equity Incentive Plan (the “2020 Plan”), pursuant to the provisions of the 2020 Plan providing for an automatic increase in the number of Common Shares reserved and available for issuance under the 2020 Plan on January 1, 2025 and (ii) 425,107 additional Common Shares under the 2020 Employee Share Purchase Plan (the “ESPP”), pursuant to the provisions of the ESPP providing for an automatic increase in the number of Common Shares reserved and available for issuance under the ESPP on January 1, 2025. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The contents of the Registrant’s Registration Statements on Form S-8 (File Nos. 333-239400, 333-255048, 333-263469, 333-270170 and 333-277451) filed with the Commission on June 24, 2020, April 6, 2021, March 11, 2022, March 1, 2023 and February 28, 2024, respectively.

    (b) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 3, 2025.

    (c) The Registrant’s Current Report on Form 8-K filed with the Commission on February  25, 2025.

    (d) The description of the Registrant’s Common Shares which is contained in the Registrant’s Registration Statement on Form 8-A filed on June 16, 2020 (File No. 001-39335) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 8.

    EXHIBITS

     

    Exhibit

    Number

      

    Description

       Incorporated by Reference  
       Schedule
    Form
         File
    Number
         Exhibit      Filing Date  
     4.1    Articles of Continuance of Repare Therapeutics Inc.      8-K        001-39335        3.1        June 23, 2020  
     4.2    Amended and Restated Bylaws of Repare Therapeutics Inc.      8-K        001-39335        3.2        June 23, 2020  
     4.3    Form of Common Share Certificate.      S-1/A        333-238822        4.1        June 15, 2020  
     5.1*    Opinion of Stikeman Elliott LLP.            
    23.1*    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.            
    23.2*    Consent of Stikeman Elliott LLP (included in Exhibit 5.1).            
    24.1*    Power of Attorney (included on the signature page of this Form S-8).             
    99.1    2020 Equity Incentive Plan.      S-1/A        333-238822        10.3        June 15, 2020  
    99.2    Form of Share Option Grant Notice and Share Option Agreement under the 2020 Equity Incentive Plan.      S-1/A        333-238822        10.4        June 15, 2020  
    99.3    Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the 2020 Equity Incentive Plan.      S-1/A        333-238822        10.5        June 15, 2020  
    99.4    2020 Employee Share Purchase Plan.      S-1/A        333-238822        10.6        June 15, 2020  
    107*    Filing fee table.            

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Montréal, Province of Québec, Canada, on this 3rd day of March, 2025.

     

    REPARE THERAPEUTICS INC.
    By:  

    /s/ Lloyd M. Segal

      Name: Lloyd M. Segal
      Title: President and Chief Executive Officer


    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Lloyd M. Segal and Steve Forte, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

      

    Position

      

    Date

    /s/ Lloyd M. Segal

    Lloyd M. Segal

       President, Chief Executive Officer and Director (Principal Executive Officer)    March 3, 2025

    /s/ Steve Forte

    Steve Forte

      

    Executive Vice President, Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

       March 3, 2025

    /s/ Thomas Civik

    Thomas Civik

       Chairman of the Board of Directors    March 3, 2025

    /s/ David Bonita, M.D.

    David Bonita, M.D.

       Director    March 3, 2025

    /s/ Samarth Kulkarni, Ph.D.

    Samarth Kulkarni, Ph.D.

       Director    March 3, 2025

    /s/ Susan Molineaux, Ph.D.

    Susan Molineaux, Ph.D.

       Director    March 3, 2025

    /s/ Ann D. Rhoads

    Ann D. Rhoads

       Director    March 3, 2025

    /s/ Carol A. Schafer

    Carol A. Schafer

       Director    March 3, 2025

    /s/ Steven H. Stein, M.D.

    Steven H. Stein, M.D.

       Director    March 3, 2025


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

    Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of the registrant has signed this registration statement or amendment thereto on the 3rd day of March, 2025.

     

    REPARE THERAPEUTICS USA INC.
    By:  

    /s/ Lloyd M. Segal

      Lloyd M. Segal
      President and Chief Executive Officer
    Get the next $RPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPTX

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    More analyst ratings

    $RPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

      Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

      5/7/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare

      4/26/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2

      1/8/24 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/17/23 4:54:43 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/3/23 5:37:44 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Financials

    Live finance-specific insights

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

      Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

      12/12/24 4:20:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

      Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

      12/10/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:00:57 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 5:05:19 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:42:55 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      5/1/25 7:08:02 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Repare Therapeutics Inc.

      DEFA14A - Repare Therapeutics Inc. (0001808158) (Filer)

      4/29/25 4:10:31 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Repare Therapeutics Inc.

      DEF 14A - Repare Therapeutics Inc. (0001808158) (Filer)

      4/29/25 4:05:33 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

      Repare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. "We have taken careful steps to evaluate all aspects of our business to ensure continued value generation,

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Ap

      4/25/25 1:00:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

      6/9/23 7:34:45 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

      2/3/23 7:35:18 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Repare Therapeutics with a new price target

      CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

      1/6/23 8:30:21 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Finance and CAO Alves Sandra Isabelle Barros was granted 4,100 shares, increasing direct ownership by 16% to 29,622 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:07:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)

      3 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:05:52 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Forte Steve

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/4/25 4:15:09 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care